QIAGEN N.V.

If you purchased QIAGEN N.V. securities and would like to join the action, please click "Join This Action" below.

QIAGEN MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF QIAGEN N.V. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – QGEN

March 3, 2020.

New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of QIAGEN N.V. (NYSE: QGEN) to Thermo Fisher Scientific Inc. for €39 per share in cash is fair to QIAGEN shareholders. On behalf of QIAGEN shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

The QIAGEN merger investigation concerns whether QIAGEN and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to: (1) obtain the best possible price for QIAGEN shareholders; (2) determine whether Thermo Fisher is underpaying for QIAGEN; and (3) disclose all material information necessary for QIAGEN shareholders to adequately assess and value the merger consideration.

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Certification

Scroll to Top